Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K is a current report filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp as indicated in metadata) on December 13, 2018. The registrant is incorporated in Nevada and is classified as an emerging growth company. The report details the departure of a senior executive.

Key Financial Metrics

The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the severance package for the departing Chief Operating Officer:

  • Final Wages and Accrued Payments: $36,814.90 (less withholdings).
  • Severance Lump Sum: $25,148.08 (representing five weeks of base salary and three months of medical insurance contributions).
  • 2018 Performance Bonus: Amount to be calculated based on annual milestones achieved; payment due by January 20, 2019.

Material Changes

The primary material change reported is the resignation of Russell DeLonzor as Chief Operating Officer (COO). His resignation is effective January 1, 2019. He is also resigning from all other positions with the Company and its subsidiaries.

Outlook, Risks, and Unusual Items

Management Commentary and Agreements: The Company entered into a Separation Agreement and Full Release of All Claims with Mr. DeLonzor. Key terms include:

  • Mr. DeLonzor must cooperate with the Company and its advisors regarding business or legal matters until January 1, 2019.
  • He is subject to non-disparagement clauses and restrictions on the use of confidential information.
  • He has released and waived any claims against the Company related to his employment and separation.

Risks and Contingencies: The filing does not disclose new material risks or contingencies beyond the standard transition risks associated with executive departure.

Investor Verification Checklist

  • Verify the appointment of a new Chief Operating Officer or interim replacement.
  • Confirm the final calculation and payment date of the 2018 performance bonus.
  • Review the full text of the Separation Agreement (Exhibit 99.1) for any additional covenants not summarized in the report.
  • Monitor subsequent filings for any impact on operational strategy or financial performance resulting from the leadership change.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.